Cargando…
How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation()
Vaccine discovery and vaccination against preventable diseases are one of most important achievements of the human race. While medical, scientific & technological advancements have kept in pace and found their way into treatment options for a vast majority of diseases, vaccines as a prevention t...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846337/ https://www.ncbi.nlm.nih.gov/pubmed/35180994 http://dx.doi.org/10.1016/j.vaccine.2021.12.038 |
_version_ | 1784651837216915456 |
---|---|
author | McGoldrick, Mic Gastineau, Thierry Wilkinson, Diane Campa, Cristiana De Clercq, Norbert Mallia-Milanes, Andrea Germay, Olivier Krishnan, Jyothsna Van Ooij, M Thien, Michael P Mlynarczyk, Peter J. Saltus, Edward Wauters, Florence Juvin, Philippe Clenet, Didier Basso, Ana Dellepiane, Nora Pagliusi, Sonia Collaço de Moraes Stávale, Monique Sivaramakrishnan, Venkatraman H Desai, Samir |
author_facet | McGoldrick, Mic Gastineau, Thierry Wilkinson, Diane Campa, Cristiana De Clercq, Norbert Mallia-Milanes, Andrea Germay, Olivier Krishnan, Jyothsna Van Ooij, M Thien, Michael P Mlynarczyk, Peter J. Saltus, Edward Wauters, Florence Juvin, Philippe Clenet, Didier Basso, Ana Dellepiane, Nora Pagliusi, Sonia Collaço de Moraes Stávale, Monique Sivaramakrishnan, Venkatraman H Desai, Samir |
author_sort | McGoldrick, Mic |
collection | PubMed |
description | Vaccine discovery and vaccination against preventable diseases are one of most important achievements of the human race. While medical, scientific & technological advancements have kept in pace and found their way into treatment options for a vast majority of diseases, vaccines as a prevention tool in the public health realm are found languishing in the gap between such innovations and their easy availability/accessibility to vulnerable populations. This paradox has been best highlighted during the unprecedented crisis of the COVID-19 pandemic. As part of a two series publication on the vaccine industry’s view on how to accelerate the availability of vaccines worldwide, this paper offers a deep dive into detailed proposals to enable this objective. These first-of-its-kind technical proposals gleaned from challenges and learnings from the COVID-19 pandemic are applicable to vaccines that are already on the market for routine pathogens as well as for production of new(er) vaccines for emerging pathogens with a public health threat potential. The technical proposals offer feasible and sustainable solutions in pivotal areas such as process validation, comparability, stability, post-approval changes, release testing, packaging, genetically modified organisms and variants, which are linked to manufacturing and quality control of vaccines. Ultimately these proposals aim to ease high regulatory complexity and heterogeneity surrounding the manufacturing & distribution of vaccines, by advocating the use of (1) Science and Risk based approaches, (2) global regulatory harmonization, (3) use of reliance, work-sharing, and recognition processes and (4) digitalization. Capitalizing & collaborating on such new-world advancements into the science of vaccines will eventually benefit the world by turning vaccines into vaccination, ensuring the health of everyone. |
format | Online Article Text |
id | pubmed-8846337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Authors. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88463372022-02-16 How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation() McGoldrick, Mic Gastineau, Thierry Wilkinson, Diane Campa, Cristiana De Clercq, Norbert Mallia-Milanes, Andrea Germay, Olivier Krishnan, Jyothsna Van Ooij, M Thien, Michael P Mlynarczyk, Peter J. Saltus, Edward Wauters, Florence Juvin, Philippe Clenet, Didier Basso, Ana Dellepiane, Nora Pagliusi, Sonia Collaço de Moraes Stávale, Monique Sivaramakrishnan, Venkatraman H Desai, Samir Vaccine Review Vaccine discovery and vaccination against preventable diseases are one of most important achievements of the human race. While medical, scientific & technological advancements have kept in pace and found their way into treatment options for a vast majority of diseases, vaccines as a prevention tool in the public health realm are found languishing in the gap between such innovations and their easy availability/accessibility to vulnerable populations. This paradox has been best highlighted during the unprecedented crisis of the COVID-19 pandemic. As part of a two series publication on the vaccine industry’s view on how to accelerate the availability of vaccines worldwide, this paper offers a deep dive into detailed proposals to enable this objective. These first-of-its-kind technical proposals gleaned from challenges and learnings from the COVID-19 pandemic are applicable to vaccines that are already on the market for routine pathogens as well as for production of new(er) vaccines for emerging pathogens with a public health threat potential. The technical proposals offer feasible and sustainable solutions in pivotal areas such as process validation, comparability, stability, post-approval changes, release testing, packaging, genetically modified organisms and variants, which are linked to manufacturing and quality control of vaccines. Ultimately these proposals aim to ease high regulatory complexity and heterogeneity surrounding the manufacturing & distribution of vaccines, by advocating the use of (1) Science and Risk based approaches, (2) global regulatory harmonization, (3) use of reliance, work-sharing, and recognition processes and (4) digitalization. Capitalizing & collaborating on such new-world advancements into the science of vaccines will eventually benefit the world by turning vaccines into vaccination, ensuring the health of everyone. The Authors. Published by Elsevier Ltd. 2022-02-23 2022-02-15 /pmc/articles/PMC8846337/ /pubmed/35180994 http://dx.doi.org/10.1016/j.vaccine.2021.12.038 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review McGoldrick, Mic Gastineau, Thierry Wilkinson, Diane Campa, Cristiana De Clercq, Norbert Mallia-Milanes, Andrea Germay, Olivier Krishnan, Jyothsna Van Ooij, M Thien, Michael P Mlynarczyk, Peter J. Saltus, Edward Wauters, Florence Juvin, Philippe Clenet, Didier Basso, Ana Dellepiane, Nora Pagliusi, Sonia Collaço de Moraes Stávale, Monique Sivaramakrishnan, Venkatraman H Desai, Samir How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation() |
title | How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation() |
title_full | How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation() |
title_fullStr | How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation() |
title_full_unstemmed | How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation() |
title_short | How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation() |
title_sort | how to accelerate the supply of vaccines to all populations worldwide? part ii: initial industry lessons learned and detailed technical reflections leveraging the covid-19 situation() |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846337/ https://www.ncbi.nlm.nih.gov/pubmed/35180994 http://dx.doi.org/10.1016/j.vaccine.2021.12.038 |
work_keys_str_mv | AT mcgoldrickmic howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT gastineauthierry howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT wilkinsondiane howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT campacristiana howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT declercqnorbert howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT malliamilanesandrea howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT germayolivier howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT krishnanjyothsna howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT vanooijm howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT thienmichaelp howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT mlynarczykpeterj howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT saltusedward howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT wautersflorence howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT juvinphilippe howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT clenetdidier howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT bassoana howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT dellepianenora howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT pagliusisonia howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT collacodemoraesstavalemonique howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT sivaramakrishnanvenkatramanh howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation AT desaisamir howtoacceleratethesupplyofvaccinestoallpopulationsworldwidepartiiinitialindustrylessonslearnedanddetailedtechnicalreflectionsleveragingthecovid19situation |